We have witnessed high volatility in the market in the earlier months of 2026, when the market hit high prices of above $100 and retreated.We have witnessed high volatility in the market in the earlier months of 2026, when the market hit high prices of above $100 and retreated.

Uranium Price Prediction: Price Holds Near $86 After Early 2026 Surge

2026/03/19 04:45
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Uranium has since undergone a leveling-off period because traders are tracking future demand indicators.

The commodity market still has steady growth in its performance over the long term. Uranium remains in the spotlight of investors as it aids the world in energy provision and the development of nuclear energy.

Uranium Futures Hold Near $86 After Earlier Market Volatility

Uranium is still performing excellently compared to the past years, although this is on a short-term basis. Statistics show that the prices rose by approximately 34.53% in the last year. The rally commenced approximately in the middle of 2025 when the demand for nuclear energy resources began to receive more intensive attention.

The trend line also indicates a significant spike in the month of February 2026 when the price of uranium shot up. Once they hit those high levels, the market started experiencing a short pullback. These movements can be found when the traders respond to sudden fluctuations in commodity prices.

According to market data from TradingEconomics, uranium futures are trading in and around $86.50 with very low daily changes. Prices fell by approximately 2.64 pounds in the last month, which is indicative of a consolidation of previous gains. This trend is an indicator that the market is balancing after high price swings.

The trade activity also rose when the price was changing drastically. An increase in volume at such sessions is an indicator of the active involvement of investors and traders in the commodity market.

Uranium Price Stability Appears After Surge Above $100

Additional data show the volume of trading also rose with the significant movement of prices, especially on the run-up to the $100 point. High volume indicates that the market participants are still interested in the market despite its recent correction.

The rally at the beginning of 2026 caused prices to reach the high mark of more than $100 and then exceeded it briefly. Uranium registered a correction after that peak that took the price back to the mid-range of the $80s.

According to the statistics of Investing.com, uranium is trading at a valuation of almost $86.50 and increasing by a very low daily rate of approximately 0.41%. According to the chart, the commodity has been volatile in the earlier part of the year.

The overall price trend over the last year is still upwards. The rally had started in mid-2025 and gained strength through early 2026, and thereafter the market started to slow. These patterns are usually experienced when rapid increases are succeeded by consolidation.

Uranium ETF Movement Shows Continued Market Participation

In the recent sessions, the ETF price has been ranging between $48.19 and $56.75. The existing levels of trading are still near the middle of that range, and this indicates moderate volatility in the market.

The volume stood at approximately 2.3 million shares, and this means that investors were involved. Increased volume is usually seen in cases where the traders are closely tracking commodity-related assets.

As per the data provided by TradingView, the Global X Uranium ETF was trading close to the price of $50.52 following a 1.14% daily growth. The price is fluctuating within the Bollinger Band range, which indicatordoes not suggest the market conditions are very volatile.

There are also indicators of changing momentum that are reflected through technical indicators. The MACD has not crossed the zero line yet, with the weakening bearish pressure. This trend indicates that the traders are watching the market to give them better signs that might determine the future price movement.

Market Opportunity
SURGE Logo
SURGE Price(SURGE)
$0.01531
$0.01531$0.01531
-6.53%
USD
SURGE (SURGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

The post Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference appeared on BitcoinEthereumNews.com. The suitcoiners are in town.  From a low-key, circular podium in the middle of a lavish New York City event hall, Strategy executive chairman Michael Saylor took the mic and opened the Bitcoin Treasuries Unconference event. He joked awkwardly about the orange ties, dresses, caps and other merch to the (mostly male) audience of who’s-who in the bitcoin treasury company world.  Once he got onto the regular beat, it was much of the same: calm and relaxed, speaking freely and with confidence, his keynote was heavy on the metaphors and larger historical stories. Treasury companies are like Rockefeller’s Standard Oil in its early years, Michael Saylor said: We’ve just discovered crude oil and now we’re making sense of the myriad ways in which we can use it — the automobile revolution and jet fuel is still well ahead of us.  Established, trillion-dollar companies not using AI because of “security concerns” make them slow and stupid — just like companies and individuals rejecting digital assets now make them poor and weak.  “I’d like to think that we understood our business five years ago; we didn’t.”  We went from a defensive investment into bitcoin, Saylor said, to opportunistic, to strategic, and finally transformational; “only then did we realize that we were different.” Michael Saylor: You Come Into My Financial History House?! Jokes aside, Michael Saylor is very welcome to the warm waters of our financial past. He acquitted himself honorably by invoking the British Consol — though mispronouncing it, and misdating it to the 1780s; Pelham’s consolidation of debts happened in the 1750s and perpetual government debt existed well before then — and comparing it to the gold standard and the future of bitcoin. He’s right that Strategy’s STRC product in many ways imitates the consols; irredeemable, perpetual debt, issued at par, with…
Share
BitcoinEthereumNews2025/09/18 02:12
Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

The post Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent? appeared on BitcoinEthereumNews.com. In brief The White House registered aliens.gov
Share
BitcoinEthereumNews2026/03/19 05:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26